title: [The fibrinolytic activity in leukemic cell lines and its alteration on all-trans retinoic acid treatment].
abstract: OBJECTIVE
  To study the fibrinolytic activity and the expression of uPAR and Annexin II in leukemic cell lines and their alterations on all-trans retinoic acid ( ATRA) treatment.
  
  
  METHODS
  The fibrinolytic activity was measured by chromogenic assay in NB4, SHI-1, K562, Jurkat and Raji cell lines. The protein expression of uPAR and Annexin II on cells surface and the mRNA expression of uPAR and Annexin II in cells of these cell lines were detected using flow cytometry and RT-PCR method respectively.
  
  
  RESULTS
  The plasmin activity in supernatant was increased significantly after incubation of SHI-1 and NB4 cells with plasminogen. The plasmin activity of NB4 cells was obviously decreased by ATRA. The plasmin activity of NB4 and SHI-1 cells was significantly decreased by uPAR monoclonal antibodies. The expressions of uPAR and Annexin II and their mRNA in SHI-1 and NB4 cells were higher than that in other cell lines. ATRA could remarkably decrease the expressions of Annexin II and uPAR and their mRNA in NB4 cells.
  
  
  CONCLUSIONS
  In leukemia cell lines, NB4 and SHI-1 cells have stronger fibrinolytic activity. Both Annexin II and uPAR on the leukemic cell membranes might contribute to this activity. The high fibrinolytic activity can be corrected by ATRA by down-regulating Annexin I and uPAR mRNA and protein expression in NB4 cells.
authors.affiliation: The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Xie
authors.forename: Zhao-Yue
authors.initials: ZY
authors.lastname: Wang
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Lan
authors.initials: L
authors.lastname: Dai
authors.forename: Xia
authors.initials: X
authors.lastname: Bai
mesh_terms: D017306:Annexin A2 / Q000096:biosynthesis* / Q000235:genetics; D045744:Cell Line, Tumor; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D007938:Leukemia / Q000378:metabolism* / Q000473:pathology*; D012333:RNA, Messenger / Q000235:genetics; D011956:Receptors, Cell Surface / Q000096:biosynthesis* / Q000235:genetics; D055293:Receptors, Urokinase Plasminogen Activator; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014212:Tretinoin / Q000494:pharmacology*
chemical_list: D017306:Annexin A2; C524898:PLAUR protein, human; D012333:RNA, Messenger; D011956:Receptors, Cell Surface; D055293:Receptors, Urokinase Plasminogen Activator; D014212:Tretinoin